Evidence map›Paper›PMID 39224663›Full record

ArticleClinical and translational radiation oncology2024

Enhanced head and neck radiotherapy target definition through multidisciplinary delineation and peer review: A prospective single-center study.

Tatiana Dragan, Kaoutar Soussy, Sylvie Beauvois, Yolene Lefebvre, Marc Lemort, Elcin Ozalp, Akos Gulyban, Manuela Burghelea, Clémence Al Wardi, Clementine Marin and 2 more

Abstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tatiana DraganDepartment of Radiation Oncology (Head and Neck Unit), Institut Jules Bordet, Hopital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles, Brussels, Belgium.
Kaoutar SoussyDepartment of Radiation Oncology, Centre Hospitalier Universitaire Hassan II, Fes, Morocco.
Sylvie BeauvoisDepartment of Radiation Oncology (Head and Neck Unit), Institut Jules Bordet, Hopital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles, Brussels, Belgium.
Yolene LefebvreDepartment of Radiology, Institut Jules Bordet, Hopital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles, Brussels, Belgium.
Marc LemortDepartment of Radiology, Institut Jules Bordet, Hopital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles, Brussels, Belgium.
Elcin OzalpDepartment of Nuclear Medecine, Institut Jules Bordet, Hopital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles, Brussels, Belgium.
Akos GulybanMedical Physics Department, Institut Jules Bordet, Université Libre de Bruxelles, Hopital Universitaire de Bruxelles (HUB), Brussels, Belgium.
Manuela BurgheleaMedical Physics Department, Institut Jules Bordet, Université Libre de Bruxelles, Hopital Universitaire de Bruxelles (HUB), Brussels, Belgium.
Clémence Al WardiDepartment of Radiation Oncology, Institut Jules Bordet, Hopital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles, Brussels, Belgium.
Clementine MarinDepartment of Nuclear Medecine, Institut Jules Bordet, Hopital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles, Brussels, Belgium.
Sofian BenkhaledDepartment of Radiation Oncology, CHUV, Lausanne University Hospital, Lausanne, Switzerland.
Dirk Van GestelDepartment of Radiation Oncology (Head and Neck Unit), Institut Jules Bordet, Hopital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles, Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study evaluates the benefit of weekly delineation and peer review by a multidisciplinary team (MDT) of radiation oncologists (ROs), radiologists (RXs), and nuclear medicine (NM) physicians in defining primary and lymph node tumor volumes (GTVp and GTVn) for head and neck cancer (HNC) radiotherapy. This study includes 30 consecutive HNC patients referred for definitive curative (chemo)-radiotherapy. Imaging data including head and neck MRI, [18F]-FDG-PET and CT scan were evaluated by the MDT. The RO identified the 'undeniable' tumor as GTVp_core and determined GTVp_max, representing the maximum tumoral volume. The MDT delineation (MDT-D) by RX and NM physicians outlined their respective primary GTVs (GTVp_RX and GTVp_NM). During the MDT meeting (MDT-M), these contours were discussed to reach a consensus on the final primary GTV (GTVp_final). In the comparative analysis of various GTVp delineations, we performed descriptive statistics and assessed two MDT-M factors: 1) the added value of MDT-M, which includes the section of GTVp_final outside GTVp_core but within GTVp_RX or GTVp_NM, and 2) the part of GTVp_final that deviates from GTVp_max, representing the area missed by the RO. For GTVn, discussions evaluated lymph node extent and malignancy, documenting findings and the frequency of disagreements. The average GTVp core and max volumes were 19.5 cc (range: 0.4-90.1) and 22.1 cc (range: 0.8-106.2), respectively. Compared to GTVp_core, MDT-D to GTVp_final added an average of 3.3 cc (range: 0-25.6) and spared an average of 1.3 cc (0-15.6). Compared to GTVp_max, MDT-D and -M added an average of 2.7 cc (range: 0-20.3) and removed 2.3 cc (0-21.3). The most frequent GTVn discussions included morphologically suspicious nodes not fixing on [18F]-FDG-PET and small [18F]-FDG-PET negative retropharyngeal lymph nodes. Multidisciplinary review of target contours in HNC is essential for accurate treatment planning, ensuring precise tumor and lymph node delineation, potentially improving local control and reducing toxicity.

Indexed as

Head and neck cancerMultidisciplinary peer reviewRadiotherapyTarget volume delineation

Identifiers

PMID39224663
PMCPMC11366888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.